Real-World Effectiveness and Safety of Adjuvant Abemaciclib Plus Endocrine Therapy in Brazilian Patients with High-Risk Hormone Receptor-positive, HER2-Negative Early Breast Cancer
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Carolina Pereira dos Santos und 4 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence Carolina Pereira Dos Santos (cps_carol94@hotmail.com) Adjuvant abemaciclib plus endocrine therapy (ET) has become the standard of care for patients with high-risk hormone receptor-positive (HR+)/HER2-negative (HER2–) early breast cancer based on phase III trial data. However, real-world evidence in Brazilian populations remains scarce. We evaluated disease-free survival (DFS), toxicity management, and predictors of recurrence. This study at a Brazilian cancer centre included patients who received adjuvant abemaciclib between January 2021 and April 2025. Demographics, tumour characteristics, treatments, and adverse events were extracted from anonymised medical records. DFS was estimated using the Kaplan–Meier method, and subgroup comparisons were performed using log-rank tests. Of the 139 patients included, the median age was 49 years (range: 26–85). A total of 60.4% (n = 84) were premenopausal, and 71.9% (n = 100) had Ki-67 ≥ 20%. Most patients received adjuvant chemotherapy (55.4%; n = 77), mainly with doxorubicin and cyclophosphamide followed by paclitaxel (AC-T; 82%, n = 114), and underwent total mastectomy (61.9%; n = 86).With a median follow-up of 15.1 months, four invasive recurrences (2.9%) were observed. The mean disease-free survival (DFS) was 35.4 months (95% CI: 34.3–36.6); the median DFS was not reached. In univariate analysis, pathological tumour size (p < 0.001) and chemotherapy regimen (p < 0.001) were significantly associated with DFS, whereas menopausal status, BRCA mutation status, Ki-67 expression, and nodal stage were not. Adverse events were reported in 88.5% of patients, including diarrhoea (68.3%), fatigue (28.1%), neutropenia (10.8%), and ALT/AST elevation (7.8%). Dose reduction was required in 38.1% (n = 53), and treatment suspension (temporary or permanent) occurred in 29.5% (n = 41), with 23.7% (n = 33) attributed to toxicity. Dose reduction was significantly associated with treatment suspension (χ² = 26.5, p < 0.001) and with toxicity (p = 0.012). However, neither dose reduction (p = 0.454) nor treatment suspension (p = 0.083) impacted DFS. Adjuvant abemaciclib was associated with a 97% 2-year DFS rate, despite frequent dose modifications. Tumour burden and chemotherapy regimen were significant predictors of early recurrence. These findings support the real-world effectiveness of abemaciclib and suggest the feasibility of toxicity-guided dose individualization without compromising efficacy. Longer follow-up is warranted to assess its impact on late recurrences and overall survival. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Carolina Pereira dos Santos, Monique Celeste Tavares, Carolina Campanholo Marques, Solange Moraes Sanches, Debora Guilherme de Alburquerque E Rodrigues de Sousa. Real-World Effectiveness and Safety of Adjuvant Abemaciclib Plus Endocrine Therapy in Brazilian Patients with High-Risk Hormone Receptor-positive, HER2-Negative Early Breast Cancer. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825271
Zitieren
APA
Santos, C. P. D., Tavares, M. C., Marques, C. C., Sanches, S. M., & Sousa, D. G. D. A. E. R. D. (2026). Real-World Effectiveness and Safety of Adjuvant Abemaciclib Plus Endocrine Therapy in Brazilian Patients with High-Risk Hormone Receptor-positive, HER2-Negative Early Breast Cancer. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825271
Vancouver
Santos CPD, Tavares MC, Marques CC, Sanches SM, Sousa DGDAERD. Real-World Effectiveness and Safety of Adjuvant Abemaciclib Plus Endocrine Therapy in Brazilian Patients with High-Risk Hormone Receptor-positive, HER2-Negative Early Breast Cancer. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825271
BibTeX
@article{Santos2026,
author = {Santos, Carolina Pereira dos and Tavares, Monique Celeste and Marques, Carolina Campanholo and Sanches, Solange Moraes and Sousa, Debora Guilherme de Alburquerque E Rodrigues de},
title = {Real-World Effectiveness and Safety of Adjuvant Abemaciclib Plus Endocrine Therapy in Brazilian Patients with High-Risk Hormone Receptor-positive, HER2-Negative Early Breast Cancer},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825271}
}
EUVIMED